Engelking L E, Gobikrushanth M, Oba M, Ambrose D J
Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton T6G 2P5, Canada.
Department of Large Animal Clinical Sciences, University of Saskatchewan, Saskatoon S7N 5B4, Canada.
JDS Commun. 2022 Jun 17;3(5):362-367. doi: 10.3168/jdsc.2022-0207. eCollection 2022 Sep.
This study evaluated the effects of dietary butyrate supplementation and oral nonsteroidal antiinflammatory drug (NSAID) administration on uterine inflammation and the interval from calving to first ovulation (ICFO; in days). We hypothesized that a combination of dietary butyrate and oral NSAID would reduce uterine inflammation and decrease ICFO. Sixty-five cows were enrolled in a 2 × 2 factorial design and assigned to receive an iso-energetic diet containing a supplement of either butyrate (fatty acid-coated calcium butyrate) or control (commercial fat and calcium carbonate mixture) at 1.42% of diet dry matter, during the calving transition period from -28 (±3) to +24 (±3) days in milk (DIM; calving = d 0). At 12 to 24 h postcalving, cows received an oral NSAID (1 mg of meloxicam/kg of BW) or a placebo (food dye). Ovarian ultrasonography was performed weekly from 14 DIM until first ovulation or up to 56 DIM. Endometrial cytology was performed at 28 DIM to assess uterine inflammation based on polymorphonuclear leukocytes (PMN). No interactions were detected between treatments. The proportions of cows with high (>18%) endometrial PMN did not differ between butyrate and control diets or between NSAID and placebo. Mean (± standard error of mean) ICFO did not differ between butyrate (28 ± 2 d) and control (25 ± 2 d) or between NSAID (29 ± 2 d) and placebo (24 ± 2 d). However, the ovulation rate up to 56 DIM (hazard ratio: 0.61; 95% confidence interval: 0.35 to 1.04) established by survival analysis tended to be lower in NSAID than in placebo. In conclusion, dietary butyrate supplementation and oral NSAID administration did not reduce endometrial inflammation or the mean ICFO, but NSAID-treated cows tended to have a lower rate of ovulation up to 56 DIM.
本研究评估了日粮中添加丁酸盐和口服非甾体抗炎药（NSAID）对子宫炎症以及从产犊到首次排卵间隔时间（ICFO，单位为天）的影响。我们假设日粮丁酸盐和口服NSAID联合使用会减轻子宫炎症并缩短ICFO。65头奶牛采用2×2析因设计，在产犊过渡期（从产犊前28（±3）天到产犊后24（±3）天，产犊日为第0天），被分配接受一种等能量日粮，该日粮含有按日粮干物质的1.42%添加的丁酸盐（脂肪酸包被的丁酸钠）或对照物（商业脂肪和碳酸钙混合物）。在产后12至24小时，奶牛接受口服NSAID（美洛昔康1毫克/千克体重）或安慰剂（食用色素）。从产后14天开始每周进行一次卵巢超声检查，直至首次排卵或直至产后56天。在产后28天进行子宫内膜细胞学检查，以基于多形核白细胞（PMN）评估子宫炎症。未检测到处理之间的交互作用。丁酸盐日粮组和对照组之间或NSAID组和安慰剂组之间，子宫内膜PMN比例高（>18%）的奶牛比例没有差异。丁酸盐组（28±2天）和对照组（25±2天）之间或NSAID组（29±2天）和安慰剂组（24±2天）之间，平均（±平均标准误）ICFO没有差异。然而，通过生存分析确定的至产后56天的排卵率（风险比：0.61；95%置信区间：0.35至1.04），NSAID组比安慰剂组有降低趋势。总之，日粮中添加丁酸盐和口服NSAID并未减轻子宫内膜炎症或缩短平均ICFO，但接受NSAID处理的奶牛至产后56天的排卵率有降低趋势。
